This project will assess new ways to protect against HIV infection and treat HIV infection using potent antibody therapies. This will help us understand how the immune system can control HIV. We will generate antibody fragments that can be produced relatively cheaply that, if successful, could lead to a viable antibody therapy for HIV.
Multistage Vaccines For The Prevention Of Tuberculosis
Funder
National Health and Medical Research Council
Funding Amount
$884,290.00
Summary
Almost two million people die from tuberculosis (TB) each year. The current vaccine, BCG, is ineffective at controlling TB and the type of immune response needed to protect against the disease is poorly understood. We have discovered new antigens of the TB bacterium, and we will combine them with novel delivery strategies to develop new TB vaccines. We will also determine the type of immune response needed to protect against TB, which will aid progression of vaccines into clinical trials.
FluMum: A Prospective Cohort Study Of Mother-infant Pairs Assessing The Effectiveness Of Maternal Influenza Vaccination In Prevention Of Influenza In Early Infancy
Funder
National Health and Medical Research Council
Funding Amount
$2,598,377.00
Summary
Influenza is a serious illness for young babies. Currently there are no vaccines that can be given to babies under 6 months of age to protect them from infection. This study aims to determine whether influenza vaccine given in pregnancy can prevent infection in babies up to 6 months of age.
Virus Vaccines That Ensure Preparedness Against Future Public Health Emergencies
Funder
National Health and Medical Research Council
Funding Amount
$862,061.00
Summary
In this proposal, we will utilize novel technology we have developed (the molecular clamp) to generate candidate subunit vaccines and therapeutic antibody treatments against four highly pathogenic viruses identified by the World Health Organization as requiring urgent R&D to prepare for future epidemics; Ebola virus, Middle East Respiratory Coronavirus, Nipah virus and Lassa fever virus. Resulting vaccines are expected to provide advantages including safety, efficacy, and thermal stability.
New Candidate Vaccines To Prevent Tuberculosis: Preclinical Assessment Of Efficacy, Safety And Mechanism Of Protection
Funder
National Health and Medical Research Council
Funding Amount
$594,133.00
Summary
Almost two million people die from tuberculosis (TB) each year. The curent vaccine, BCG, is ineffective at controlling TB and and the type of immune response needed to protect against the disease is poorly understood. We have discovered new antigens of the TB bacterium, and we will combine them with our innovative vaccine technology to develop new vaccines to control TB. We will also try and understand why BCG is not effective, and use this information to further improve TB vaccination.
Uncovering The Epigenetic Landscape That Regulates Human Transcriptional Memory
Funder
National Health and Medical Research Council
Funding Amount
$708,208.00
Summary
The ‘T cells’ in our bodies develop a memory of previous infections so that we do not become ill from them again. However, we do not fully understand how this memory works and it fails as we get old. We will use cutting-edge techniques to examine the detailed molecular wiring that ‘remembers’ viruses and see how it changes over time. This is hoped to facilitate the design of new age-specific vaccines and drugs and promote a more personalised approach to preventing and treating immune diseases.
A Multi-centre, Double-blind, Randomised Controlled Trial To Evaluate The Efficacy Of 10 Valent-pneumococcal-Protein D Conjugate Vaccine In Reducing Respiratory Exacerbations In Children Aged ? 18 Months With Suppurative Lung Disease
Funder
National Health and Medical Research Council
Funding Amount
$1,160,660.00
Summary
Chronic suppurative (ie infected) lung diseases in children are major causes of poor health and deaths worldwide. Repeated childhood infections contribute to poor lung health in adults. The most common organism causing infection is non-typeable Haemophilus influenzae (NTHi). This study aims to determine whether a vaccine against NTHi can reduce repeated respiratory infections in children. If so, vaccination may lead to substantial improvements in current/ future lung health, and considerable dir ....Chronic suppurative (ie infected) lung diseases in children are major causes of poor health and deaths worldwide. Repeated childhood infections contribute to poor lung health in adults. The most common organism causing infection is non-typeable Haemophilus influenzae (NTHi). This study aims to determine whether a vaccine against NTHi can reduce repeated respiratory infections in children. If so, vaccination may lead to substantial improvements in current/ future lung health, and considerable direct and indirect cost of disease savings.Read moreRead less
Does Pneumococcal Vaccination Protect Against Cardiovascular Disease? A Randomised Placebo-controlled Double Blind Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,849,245.00
Summary
Australian researchers have set up a novel multi-centre trial to investigate the effects of the pneumococcal vaccination in reducing heart attacks and stroke. People aged 55 to 61 from 6 sites around Australia will be invited to participate in the study. The selected participants will attend a clinic in their area and will be randomly given the pneumococcal vaccine or a placebo vaccine. Outcomes on the expected 6000 participants will be ascertained by health record linkage with government databa ....Australian researchers have set up a novel multi-centre trial to investigate the effects of the pneumococcal vaccination in reducing heart attacks and stroke. People aged 55 to 61 from 6 sites around Australia will be invited to participate in the study. The selected participants will attend a clinic in their area and will be randomly given the pneumococcal vaccine or a placebo vaccine. Outcomes on the expected 6000 participants will be ascertained by health record linkage with government databases after 4 years.Read moreRead less
Determining Regulators Of ILC3 In Mucosal Barrier Function And Immune Homeostasis
Funder
National Health and Medical Research Council
Funding Amount
$705,209.00
Summary
Innate lymphoid cells (ILCs) are specialized cells that defend the body against invading microorganisms at the body’s surfaces, mediate pathogen clearance and tissue repair but may also drive inflammatory conditions such as allergic asthma and inflammatory bowel disease. We will investigate the molecular switches that regulate this novel cell type and potentially uncover novel molecules or pathways for therapeutic targets.
The Role Of Cytokines In Tumor-induced Immunosuppression
Funder
National Health and Medical Research Council
Funding Amount
$754,473.00
Summary
Cancer-induced immune suppression is a major obstacle to the effective treatment of many cancers. We have shown that the cytokine IL-23, plays an important role in cancer initiation, growth and development. My project aims to characterize the cells that produce IL-23 in the cancer microenvironment and define how it suppresses cells of the immune system. A greater understanding of this cytokine’s mechanism of action will enable the rational improvement of treatments for patients with cancer